Summer 2026

Product Management Intern

Posted on 2/26/2026

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$28 - $30/hr

Pleasanton, CA, USA

In Person

Travel required: 25%.

Category
Product (1)
Required Skills
Power BI
Python
Usability Testing/Engineering
R
Product Management
Figma
SQL
Excel/Numbers/Sheets
Requirements
  • Education: Currently pursuing a Bachelor’s or Master’s degree in Human‑Computer Interaction (HCI), UX Research, Cognitive Science, Biomedical Engineering, Product Management, or a related field, or equivalent relevant academic experience.
  • Minimum 0years experience
  • Work location: Pleasanton, CA
  • Travel: 25%
  • Full time employment
  • Required Hard Skills
  • Familiarity with usability testing or human centered design principles
  • Experience organizing, documenting, and synthesizing research or project data
  • Ability to build and maintain lightweight dashboards or trackers to monitor Early Market Evaluation (EME) throughput, usability findings, issue severity, ownership, and mitigation progress
  • Experience working with structured data using tools such as Excel or Google Sheets (e.g., tables, filters, basic formulas, pivots)
  • Exposure to UX or research tools such as Figma, Notion, Airtable, Miro, Qualtrics, Power BI, or similar tools (academic or project experience acceptable)
  • Required Soft Skills
  • Strong written and verbal communication skills
  • Excellent attention to detail and organizational skills
  • Ability to collaborate effectively with cross functional teams
  • Analytical thinking and problem solving skills
  • Ability to follow instructions, manage multiple tasks, and execute in a fast paced environment
  • Computer / Technology Competency
  • Proficiency with Microsoft Office tools (Excel, PowerPoint, Word) or Google Workspace, and comfort learning new software tools and systems as required. Exposure to basic programming or scripting relevant to data analysis or research workflows (e.g., Python, SQL, R, or similar), gained through coursework, projects, or internships
  • Physical Requirements
  • Ability to sit or stand for extended periods while working at a computer, attend meetings, and perform standard office‑based tasks.
  • Compliance with relevant county, state, and Federal rules regarding vaccinations.
Responsibilities
  • Support planning and execution of multiple usability testing cycles by preparing test scripts, session checklists, notetaking templates, and maintaining the master usability test calendar.
  • Stand up and maintain lightweight dashboards that track Early Market Evaluation (EME) throughput, usability findings, issue severity, ownership, and mitigation progress, providing regular visibility into testing outcomes and followup status.
  • Manage and maintain the central repository of usability artifacts, ensuring all test sessions are fully documented, accurately categorized, and easily accessible to Product, Engineering, and Design stakeholders.
  • Attend and support usability test sessions, including notetaking, observation logging, and coordination with external partners and internal team members.
  • Assist with preparation of presentation materials and readouts for cross functional reviews, leadership updates, or milestone checkpoints as needed.
Desired Qualifications
  • Coursework or experience in usability testing or humancentered design.
  • Familiarity with tools like Figma, Notion, Airtable, Miro, Qualtrics, or similar.
  • Working knowledge of data analysis or dashboarding tools such as Excel (advanced formulas, pivots), Google Sheets, Power BI, Tableau, Airtable, or similar platforms

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Calyxo raised $40 million in Series F from specialist healthcare investors.
  • CVAC crossed 40,000 kidney stone procedures, strengthening physician referenceability.
  • Funding supports commercial expansion and health-economic evidence generation.

What critics are saying

  • Boston Scientific already owns installed ureteroscopy franchises in most hospitals.
  • A 2024 MAUDE report documented sepsis and death after CVAC use.
  • Calyxo still depends on early evidence; larger studies can narrow differentiation.

What makes Calyxo unique

  • CVAC continuously aspirates stone fragments during and after laser lithotripsy.
  • FDA cleared CVAC in March 2024, lowering regulatory friction.
  • ASPIRE showed superior stone clearance and lower residual stone volume versus URS.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE